Market Name: Humira

Generic Name: Adalimumab

Humira, manufactured by Abbott Pharmaceuticals, is a Tumor Necrosis Factor blocker. It is designed to reduce the signs and symptoms of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn’s disease.

In February of 2007, the FDA added a black box warning to Humira’s prescribing information advising patients and health care professionals of the risk of serious infections, including tuberculosis, related to the use of Humira.

Black Box Warning Date: February 2007

FDA Link: Humira